Previous 10 | Next 10 |
ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results o...
AxoGen (AXGN) lost ~3.6% in the post-market after announcing its decision to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June 1, subject to ongoing discussions with the FDA on its regulatory classification.The decision not to market Aviv...
ALACHUA, Fla. and TAMPA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president and Peter...
AxoGen, Inc. (AXGN) Q1 2021 Earnings Conference Call May 05, 2021 04:30 PM ET Company Participants Peter Mariani - Executive Vice President and Chief Financial Officer Karen Zaderej - Chairman, President and Chief Executive Officer Conference Call Participants Jaime Morgan - SVB Leerink Brand...
ALACHUA, Fla. and TAMPA, Fla. , May 06, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Peter J. Mariani, executive vice president and c...
Image source: The Motley Fool. AxoGen Inc (NASDAQ: AXGN) Q1 2021 Earnings Call May 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AxoGen Inc (AXGN) Q1 2021 Earnings Call Transcript
AxoGen (AXGN): Q1 Non-GAAP EPS of -$0.08 beats by $0.07; GAAP EPS of -$0.16 beats by $0.06.Revenue of $31.03M (+27.9% Y/Y) beats by $3.39M.Press Release For further details see: AxoGen EPS beats by $0.07, beats on revenue
ALACHUA, Fla. and TAMPA, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31...
ALACHUA Fla. and TAMPA, Fla., April 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report first quarter 2021 financial results on...
AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to support the company's key products, with patients experience reduced pain/improved sensa...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...